On March 27, Peking Sinovac Holdings (Group) Co., Ltd. (hereinafter referred to as 'Sinovac Holdings') announced that its subsidiary Beijing Sinovac Biotech Co., Ltd. collaborated with Xingmeng Biomedical (Suzhou) Co., Ltd. (hereinafter referred to as 'Xingmeng Biomedical') to jointly apply for the Class I new drug SNA02-48 injection, which has been approved for clinical implied licensing. This product is a recombinant fully human monoclonal antibody targeting tetanus toxin. In addition to the tetanus monoclonal antibody, Sinovac Holdings' application for the tetanus vaccine has been accepted in April 2024.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Hot search first! Details of the Xiaomi SU7 collision and explosion incident on the highway have been revealed, and the company's stock price fell by more than 6% at one point.
Lei Jun responds to the Anhui SU7 accident: No matter what happens, Xiaomi will not evade.
Confirmed! Beijing time at 3 AM on Thursday, Trump will officially announce tariff measures.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
科兴控股:抗破伤风毒素单抗SNA02-48注射液获批临床默示许可
Sinovac Holdings: The monoclonal antibody SNA02-48 injection targeting tetanus toxin has been approved for clinical implied licensing.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 390
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report